Tranylcypromine-maprotiline

From Psychiatrienet
Revision as of 09:04, 7 October 2015 by Anoek (talk | contribs)
Jump to: navigation, search
Tranylcypromine
Type Antidepressant
Group MAO-I
links
Medscape Tranylcypromine
PubChem 5530
PubMed Tranylcypromine
Kompas (Dutch) Tranylcypromine
Wikipedia Tranylcypromine
Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline

Switch medication from tranylcypromine to maprotiline.[1] [2]

Nietinrijdenbord.png Stop tranylcypromine
  • Gradually decrease the dosage of tranylcypromine with 10-20 mg/week.
  • When a dosage of 10 mg/day is reached, stop administration.
Eenrichtingbord.png Start maprotiline
  • Day 1-14: a wash-out period of two weeks is necessary.
  • Day 15: start maprotiline after this period in a low dosage of 25 mg/day.
Infobord.png More information
  • Occurrence of the serotonin syndrome is possible without a wash-out period.
  • The wash-out period is necessary for the MAO enzymes to restore their function.
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.